Skip to main content

Table 3 Subgroup analysis (proportion of patients meeting exclusion criteria by gender and ethnicity)

From: Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients

Characteristic SOF/VEL ASTRAL-1
No. excluded (%)
Difference
(sig level)
GLE/PIB Expedition-2 No. excluded (%) Difference
(sig level)
Gender
 Female (N = 72) 65 (90)   67 (93)  
 Male (N = 147) 130 (88)   131 (89)  
   1.9% (p 0.673)   3.9% (p 0.359)
Ethnicity
 Black (N = 117) 108 (92)   110 (94)  
 Non-black (N = 102) 87 (85)   88 (86)  
   7% (p 0.099)   7.7% (p 0.054)
  1. GLE glecaprevir, PIB pibrentasvir, SOF sofosbuvir, VEL velpatasvir